Skip to main content
. Author manuscript; available in PMC: 2014 Jun 12.
Published in final edited form as: Br J Haematol. 2013 Mar 11;161(4):508–516. doi: 10.1111/bjh.12274

Fig. 5.

Fig. 5

Overall survival by (A, B) JAK2 V617F mutation status, (C, D) baseline IPSS risk category, (E, F) baseline haemoglobin level and (G, H) baseline palpable spleen length. *Patients who received ≥1 unit of RBC transfusions within 12 weeks before baseline were assigned to the haemoglobin <100-g/l subgroup. HR, hazard ratio; IPSS, International Prognostic Scoring System; RBC, red blood cell.